News
The US FDA has cleared BlackfinBio's application for a Phase I/II trial of BFB-101, an AAV gene therapy designed to treat ...
Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...
Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...
MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...
A Phase I/II trial by Japan’s Kyoto University Hospital and CiRA team has demonstrated outcomes with allogeneic iPS ...
Renibus has completed subject enrolment for the Phase III PROTECT trial of RBT-1 in minimising post-operative risk in cardiac ...
The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...
The Sabin Vaccine Institute has begun a trial to evaluate its Marburg vaccine, with the first doses being given to subjects ...
Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...
Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.
Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an IDMC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results